Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease

Catheterization and Cardiovascular Interventions

Volumn 72, Issue 1, 2008, Pages 116-120

  Baron, Suzanne J ^a   Yeh, Robert W ^b   Cruz Gonzalez, Ignacio ^a   Healy, Josephine L ^a   Pomerantsev, Eugene ^a   Garasic, Joseph ^a   Drachman, Douglas ^a   Rosenfield, Kenneth ^a   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Argatroban; Endovascular intervention; Heparin induced thrombocytopenia; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; HEPARIN; WARFARIN;

AGED; ARTICLE; BLEEDING TENDENCY; BLOOD CLOT LYSIS; CLINICAL ARTICLE; DEATH; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HOSPITALIZATION; HUMAN; LEG AMPUTATION; LEG REVASCULARIZATION; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REFERENCE DATABASE; THERAPY EFFECT; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANGIOPLASTY; ANTICOAGULANTS; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PIPECOLIC ACIDS; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 47549085223     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21595     Document Type: Article

References (31)

1. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the NHANES 1999-2000. Circulation 2004;110:738-743.
2. Anderson PL, Gelijns A, Moskowitz A, et al. Understanding trends in inpatient surgical volume: Vascular interventions, 1980-2000. J Vasc Surg 2004;39:1200-1208.
3. Horsewood P, Warkentin TE, Hayward CPM, Kelton JG. The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 1996;95:161-167.
4. Warkentin TE, Hayward CPM, Boshkov LK, Santos AV, Sheppard JAI, Bode AP, Kelton JG. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699.
5. Berry CN, Girardot C, Lecoffre C, Lunven C. Effects of the synthetic thrombin inhibitor argatroban on fibrin-or clot-incorporated thrombin: Comparison with heparin and recombinant Hirudin. Thromb Haemost 1994;72:381-386.
6. Lewis BE, Wallis DE, Leya F, et al. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843.
7. Jang IK, Brown DF, Giugliano RP, Anderson HV, Losordo D, Nicolau JC, Dutra OP, Bazzino O, Viamonte VM, Norbady R, Liprandi AS, Massey TJ, Dinsmore R, Schwarz RP Jr. A multi-center, randomized, study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial infarction with novastan and T-PA (MINT) study. J Am Coll Cardiol 1999;33:1879-1885.
8. Behar S, Hod H, Kaplinski E. Argatroban versus heparin as adjuvant therapy to thrombolysis for actue myocardial infarction: Safety considerations-ARGAMI-2 Study. Circulation 1998;98 (Suppl 17): 1453-1454.
9. Kobayashi S, Tazaki Y. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis. Semin Thromb Hemost 1997; 23:531-534.
10. Lewis BE, Matthai WH Jr, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 2002;57:177-184.
11. Jang IK, Lewis BE, Matthai WH Jr., Kleiman NS. Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study. J Thromb Thrombolysis 2004;18:31-37.
12. Cruz-Gonzalez I, Sanchez-Ledesma M, Baron SJ, Healy JL, Watanabe H, Osakabe M, Yeh RW, Jang IK. Efficacy and sagety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary synfrome. J Thromb Thrombolysis 2007; Jul 15 [Epub ahead of print].
13. Chesebro JH, Knatterud, Roberts R, et al. Thrombolysis in myocardial infarction (TIMIT) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987;76:142-154.
14. Rice L. Heparin induced thrombocytopenia: Myths and misconceptions (that will cause trouble for you and your patient). Arch Intern Med 2004;164:1961-1964.
15. Kelton JG. Heparin-induced thrombocytopenia: An overview. Blood Rev 2002;16:77-80.
16. Baglin TP. Heparin-induced thrombocytopenia/thrombosis syndrome (HIT): Diagnosis and treatment. Platelets 1997;8:72-82.
17. Warkentin TE, Kelton JG. A 14 year study of heparin-induced thrombocytopenia. Am J Med 1996;101:502-507.
18. Wallis DE, Workman DL, Lewis BE, Steen L, Pifarre R, Moran JF. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia. Am J Med 1999;106:629-635.
19. Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-oinduced thrombocytopenia. Arch Intern Med 2003;163:1849-1856.
20. Lunven C, Gauffeny C, Lecoffre C, et al. Inhibition by argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin. Thromb Haemost 1996;75:154-160.
21. Jang IK, Gold HR, Leinbach RC, et al. Persistent inhibition of artieral thrombosis by a 1-hour intravenous infusion of argatroban, a selective thrombin inhibitor. Coron Artery Dis 1992;2: 407-414.
22. Jang IK, Gold HK, Leinbach RC, et al. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circ Res 1990;67:1552-1561.
23. Ueki Y, Matsumoto K, Kizaki Y, Yoshida K, Matsunaga Y, Yano M, Miyake S, Tominaga Y, Eguchi K. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: Placebo-controlled study. J Thromb Thrombolysis 1999;8:131-137.
24. Fareed J, Jeske WP. Small-molecule direct antithrombins: Argatroban. Best Pract Res Clin Haematol 2004;17:127-138.
25. LaMonte MP, Marshall LN, Wang DZ, et al. Argatroban anticoagulation in patients with acute ischemic stroke. Stroke 2004;35:1677-1682.
26. Jang IK, Hursting MJ. When heparins promote thrombosis: Review of heparin-induced thrombocytopenia. Circulation 2005; 111:2671-2683.
27. Long-term mortality and its predictor's in patients with critical leg ischaemia. The I.C.A.I. Group. Eur J Vasc Endocasv Surg 1997;14:91-95.
28. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal mesenteric, and abdominal aortic): A collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery. Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; Transatlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463.
29. Jang IK, Gold HK, Ziskind AA, Leinbach RC, Fallon JT, Collen D. Prevention of platelet-rich arterial thrombosis by selective thrombin inhibition. Circulation 1989;81:219-225.
30. Kawano H, Tomaru T, Omata M, Okada R, Uchida Y. Adjunctive therapy with an antithrommbotic drug can prevent reocclusion and induce residual thrombus reduction after percutaneous transcatheter angioplasty of the thrombotic lesions. J Thromb Thrombolysis 1997;4:293-300.
31. Matsuo T, Kario K, Matsuda S, Yamaguchi N, Kakishita E. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban. J Thromb Thrombolysis 1995;2:131-136.